YHR213W-A Antibody

What is YHR213W-A and why is it significant for yeast research?

YHR213W-A is an uncharacterized protein in Saccharomyces cerevisiae (baker's yeast, strain 204508/S288c) that has been identified through genomic analysis . The protein belongs to a class of overlooked genes in yeast that were not initially annotated in the yeast genome but have since been identified through integrated experimental and computational approaches .

Studies using HA-tagged versions of similar overlooked proteins (such as YHR137C-A and YMR272W-A) have revealed that these proteins typically localize to specific cellular compartments, with some showing cytoplasmic distribution with concentration around the nuclear rim and endoplasmic reticulum . Understanding YHR213W-A's function and localization contributes to our comprehensive knowledge of the yeast proteome and potentially uncovers new cellular pathways.

What types of YHR213W-A antibodies are commercially available?

Currently available YHR213W-A antibodies include:

• Polyclonal antibodies: Typically rabbit-derived anti-Saccharomyces cerevisiae YHR213W-A polyclonal antibodies that have undergone antigen-affinity purification

• Isotype: Most commonly IgG

• Applications: Validated for ELISA and Western Blot analysis

These antibodies are designed to recognize the native or recombinant forms of the uncharacterized YHR213W-A protein. For researchers requiring custom antibodies against this target, several service providers offer custom antibody development options, though this is typically only necessary for specialized applications .

How does the structure of the YHR213W-A antibody compare to other research antibodies?

Like all antibodies, YHR213W-A antibodies consist of a Y-shaped molecule with three equal-sized regions. The structure includes:

• A flexible hinge joining the antibody stalk (Fc) region to the arms

• Two arms containing F(ab) regions that function to bind the YHR213W-A antigen

• Heavy and light chains in each arm, with variable domains at the antigen-binding site

For polyclonal YHR213W-A antibodies, there is natural variation in the exact binding epitopes across the antibody population, providing recognition of multiple epitopes on the target protein. This is advantageous for detection of uncharacterized proteins like YHR213W-A where the optimal epitopes may not be well-defined .

What are the validated applications for YHR213W-A antibodies?

YHR213W-A antibodies have been validated for the following applications:

• ELISA (Enzyme-Linked Immunosorbent Assay): For quantitative detection of YHR213W-A in yeast lysates

• Western Blot: For identification of YHR213W-A protein size and expression levels

• Immunofluorescence: Similar overlooked yeast proteins have been successfully studied using immunofluorescence with HA-tagged versions, suggesting a similar approach would work for YHR213W-A

When designing experiments, researchers should note that for uncharacterized proteins like YHR213W-A, additional validation steps may be necessary to confirm specificity and sensitivity in your particular experimental context .

How should I validate a YHR213W-A antibody before use in experiments?

A comprehensive validation protocol for YHR213W-A antibodies should include:

• Positive control testing: Using recombinant YHR213W-A protein (available with ≥85% purity as determined by SDS-PAGE)

• Negative control testing: Using wild-type yeast strains and YHR213W-A knockout strains

• Cross-reactivity assessment: Testing against closely related yeast proteins

• Specificity validation: Confirming single band detection at the predicted molecular weight in Western blot

• Titration experiments: Determining optimal antibody concentration for each application

For uncharacterized proteins like YHR213W-A, comparison with epitope-tagged versions (e.g., HA-tagged YHR213W-A) can provide additional validation by confirming co-localization or similar expression patterns .

What controls should I include when using YHR213W-A antibodies?

To ensure experimental rigor when working with YHR213W-A antibodies, include the following controls:

For immunofluorescence studies, include DAPI staining to visualize nuclei, as has been done with similar proteins to determine subcellular localization patterns .

How can I use YHR213W-A antibodies for protein localization studies?

For subcellular localization of YHR213W-A:

• Immunofluorescence approach:

  • Fix yeast cells with formaldehyde (typically 3.7%)

  • Digest cell wall with zymolyase

  • Permeabilize with detergent (0.1% Triton X-100)

  • Block with BSA or normal serum

  • Incubate with YHR213W-A primary antibody

  • Detect with fluorophore-conjugated secondary antibody

  • Co-stain with DAPI for nuclear visualization

• Comparison with known patterns:
  Previous studies of similar overlooked yeast proteins have shown distinct localization patterns:

  • Cytoplasmic distribution with concentration around nuclear rim and ER (YHR137C-A, YMR272W-A)

  • Punctate cytoplasmic staining (YER023C-A, YGR174W-A)

  • Granular staining of cytoplasm and nucleus (YPL135C-A)

• Validation strategy:
  Compare results from antibody staining with localization of epitope-tagged YHR213W-A (e.g., HA-tagged or GFP-fusion) to confirm findings .

How do I troubleshoot weak or non-specific signals with YHR213W-A antibodies?

When encountering problems with YHR213W-A antibody signals:

For weak signals:

• Increase antibody concentration (perform titration from 1:100 to 1:5000)

• Extend primary antibody incubation time (overnight at 4°C)

• Optimize antigen retrieval methods for fixed samples

• Use signal amplification systems (e.g., biotin-streptavidin)

• Increase protein loading for Western blots

For non-specific signals:

• Increase blocking stringency (5% BSA or 5% milk, 0.1% Tween-20)

• Perform additional washes with higher detergent concentration

• Pre-adsorb antibody with yeast lysate lacking YHR213W-A

• Use antigen-affinity purified antibody fractions

• Decrease antibody concentration after determining optimal dilution

For validation:
Compare results with those obtained using alternative detection methods, such as epitope-tagging approaches that have been successful with similar yeast proteins .

What considerations are important when using YHR213W-A antibodies across different yeast strains?

When extending YHR213W-A antibody use to multiple yeast strains:

• Sequence variation assessment:

  • Check for YHR213W-A sequence conservation across target strains

  • Perform bioinformatic analysis to identify potential epitope differences

  • Consider strain-specific validation for highly divergent strains

• Expression level differences:

  • YHR213W-A expression may vary between laboratory and wild strains

  • Quantitative methods like qPCR should confirm transcript presence before antibody studies

  • Similar overlooked genes have shown strain-specific expression patterns

• Cross-reactivity testing:

  • Test antibody against lysates from multiple strains

  • Include knockout controls when available

  • Compare with results from tagged protein variants

• Genetic background effects:

  • Some yeast strains have genomic duplications that may affect detection specificity

  • Strain-specific protein modification might alter epitope accessibility

  • Consider genome sequencing data when interpreting results across strains

How do I quantify and normalize YHR213W-A expression data?

For accurate quantification of YHR213W-A expression:

• Western blot quantification:

  • Use digital imaging and densitometry software

  • Include a standard curve with recombinant YHR213W-A protein

  • Normalize to loading controls (e.g., actin, GAPDH, or total protein stain)

  • Apply lane-specific background subtraction

  • Report data as fold-change relative to control conditions

• Immunofluorescence quantification:

  • Measure mean fluorescence intensity across multiple cells (n>50)

  • Subtract background from cell-free areas

  • Define regions of interest based on cellular compartments

  • Apply consistent threshold settings across all experimental conditions

  • Report intensity data with statistical analysis

• ELISA quantification:

  • Generate standard curve using recombinant YHR213W-A

  • Ensure readings fall within the linear range of detection

  • Normalize to total protein concentration

  • Include technical replicates (minimum triplicate wells)

  • Apply appropriate curve-fitting methods

What are the limitations of using antibodies to study uncharacterized proteins like YHR213W-A?

Important limitations to consider include:

• Epitope accessibility issues:

  • Post-translational modifications may mask epitopes

  • Protein-protein interactions might block antibody binding sites

  • Conformational epitopes may be lost in denatured samples

• Validation challenges:

  • Lack of well-characterized positive controls

  • Difficulty confirming specificity without knockout controls

  • Limited information about potential cross-reactivity

• Expression level concerns:

  • Uncharacterized proteins often have low expression levels

  • Temporal or condition-specific expression patterns may require optimization

  • Antibody sensitivity may be insufficient for detection at endogenous levels

• Functional interpretation constraints:

  • Difficulty correlating detected expression with unknown function

  • Limited ability to interpret phenotypic effects of antibody binding

  • Challenges in distinguishing between paralogs or gene family members

Alternative approaches, such as epitope tagging combined with detection by tag-specific antibodies, can overcome some of these limitations and provide complementary data .

What methodological approaches can distinguish between YHR213W-A and similar yeast proteins?

To ensure specificity when studying proteins with potential homology:

• Bioinformatic analysis:

  • Perform sequence alignment of YHR213W-A with potential homologs

  • Identify unique regions suitable for specific antibody targeting

  • Assess cross-reactivity potential through epitope prediction tools

• Experimental validation:

  • Use recombinant proteins of each homolog in Western blot comparisons

  • Perform immunoprecipitation followed by mass spectrometry

  • Create knockout strains for each homolog and test antibody specificity

• Competition assays:

  • Pre-incubate antibody with purified recombinant YHR213W-A protein

  • Compare binding patterns before and after competition

  • Observe elimination of specific signals while non-specific signals remain

• Comparative localization:

  • Create strains with differentially tagged homologs (e.g., YHR213W-A-GFP, YHR213W-B-RFP)

  • Compare antibody staining patterns with direct fluorescence patterns

  • Identify unique vs. overlapping localization features

How can YHR213W-A antibodies contribute to studies of gene duplication in yeast?

YHR213W-A and related proteins provide a model system for studying gene duplication events:

• Genomic analysis approaches:

  • YHR213W-A may share similarities with YHR213W-B and other duplication products

  • Compare antibody detection patterns across duplicated genes

  • Combine with whole genome sequencing to identify strain-specific duplications

  • Quantify expression differences between duplicated genes using validated antibodies

• Evolutionary implications:

  • Antibody-based detection of differential expression can reveal functional diversification

  • Study the regulation of duplicated genes under different conditions

  • Compare conservation patterns across yeast species using cross-reactive antibodies

• Functional divergence analysis:

  • For gene pairs like YHR213W-A and YHR213W-B, antibodies can reveal:

    • Differential subcellular localization

    • Condition-specific expression patterns

    • Unique protein-protein interactions

  • These findings help determine whether duplicates have undergone neofunctionalization or subfunctionalization

What strategies exist for developing monoclonal antibodies against poorly immunogenic yeast proteins like YHR213W-A?

For challenging yeast proteins that may have poor immunogenicity:

• Immunization optimization:

  • Use highly purified recombinant YHR213W-A protein (≥85% purity)

  • Test multiple adjuvants (Freund's, alum, CpG-based)

  • Implement extended immunization schedules with boosting

  • Consider DNA immunization followed by protein boosting

• Carrier protein conjugation:

  • Fuse YHR213W-A to highly immunogenic carrier proteins (KLH, BSA)

  • Use immunogenic peptide tags (FLAG, HA) in recombinant constructs

  • Design chimeric proteins exposing multiple potential epitopes

• Hybridoma screening optimization:

  • Implement high-throughput ELISA screening

  • Use both native and denatured protein in screening assays

  • Apply phage display technology to select high-affinity binders

  • Screen against multiple conformational states of the protein

• Advanced antibody engineering:

  • Apply synthetic antibody library screening approaches

  • Consider yeast surface display for selection of binding domains

  • Employ affinity maturation techniques to improve binding characteristics

The production of monoclonal antibodies would complement existing polyclonal reagents and potentially offer improved specificity for detecting YHR213W-A in complex samples.

How does research on YHR213W-A antibodies relate to broader studies of overlooked proteins in eukaryotes?

YHR213W-A antibody research contributes to the larger field of cryptic gene discovery:

• Methodological parallels:

  • Techniques developed for YHR213W-A detection mirror approaches used for other overlooked genes

  • Antibody-based validation complements transcriptomic and genomic approaches

  • Similar overlooked genes (YHR137C-A, YMR272W-A, YER023C-A, YGR174W-A, YPL135C-A) have been successfully studied using antibody-based approaches

• Research integration:

  • YHR213W-A antibody studies build upon foundational work identifying overlooked genes through:

    • Transposon mutagenesis with β-galactosidase reporters

    • RNA microarray analysis

    • Sequence analysis with custom programs like ORFSEEK

  • This combined approach validates protein expression of computationally predicted genes

• Evolutionary considerations:

  • Antibodies help determine whether overlooked proteins are functional or pseudogenes

  • Cross-species reactivity testing can establish evolutionary conservation

  • Comparative proteomics enables reconstruction of evolutionary histories of gene families

What can be learned about epitope binding by studying antibody interactions with uncharacterized proteins?

Studying antibody-epitope interactions with uncharacterized proteins offers unique insights:

• Novel binding motif discovery:

  • Unbiased epitope mapping may reveal previously unknown antibody recognition patterns

  • Similar to how YYDRxG motifs were identified in SARS-CoV-2 antibodies

  • Epitope characterization can identify conserved structural elements across protein families

• Structure-function relationships:

  • Antibody binding sites can reveal functional domains in uncharacterized proteins

  • Neutralizing vs. non-neutralizing epitopes provide clues about critical regions

  • Competition assays between different antibodies help construct epitope maps

• Methodological approaches:

  • X-ray crystallography of antibody-antigen complexes reveals precise binding interfaces

  • Hydrogen-deuterium exchange mass spectrometry identifies protected regions upon binding

  • Alanine scanning mutagenesis determines critical residues for antibody recognition

• Translational applications:

  • Knowledge gained from studying YHR213W-A epitopes might inform strategies for targeting other uncharacterized proteins

  • Epitope conservation analysis across species informs antibody cross-reactivity potential

This research parallels approaches used in therapeutic antibody development, where understanding precise epitope characteristics has been crucial for developing broadly neutralizing antibodies against pathogens .

How might YHR213W-A antibodies contribute to systems biology approaches in yeast research?

YHR213W-A antibodies can enhance systems biology research through:

• Interactome mapping:

  • Immunoprecipitation coupled with mass spectrometry to identify protein-protein interactions

  • Proximity labeling techniques (BioID, APEX) using YHR213W-A as bait

  • Integration of interaction data into existing yeast protein networks

  • Comparison of interaction patterns across growth conditions and stress responses

• Regulatory network analysis:

  • ChIP-seq to identify transcription factors regulating YHR213W-A expression

  • Correlation of protein abundance (antibody-based) with transcript levels

  • Identification of post-transcriptional regulatory mechanisms

  • Multi-omic data integration to position YHR213W-A in regulatory hierarchies

• Functional genomics screening:

  • Antibody-based phenotypic screens following genetic perturbations

  • Systematic localization studies across gene deletion libraries

  • Quantitative analysis of expression changes in response to environmental challenges

  • Integration with existing datasets for overlooked genes to identify functional patterns

What advanced applications could emerge from developing nanobodies or alternative binding proteins against YHR213W-A?

Next-generation binding reagents offer exciting possibilities:

• Intracellular applications:

  • Nanobodies or DARPins expressed within yeast cells can track YHR213W-A in living cells

  • Proximity-dependent labeling using nanobody-enzyme fusions

  • Targeted protein degradation using nanobody-based degrons

  • Modulation of YHR213W-A function through intrabody binding

• Super-resolution microscopy:

  • Small binding proteins labeled with bright fluorophores enable higher resolution imaging

  • Multi-color nanobody labeling for co-localization studies

  • Single-molecule tracking of YHR213W-A dynamics

  • Correlative light and electron microscopy using nanobody-gold conjugates

• Biosensor development:

  • Creation of FRET-based sensors using nanobody pairs

  • Split-protein complementation assays to detect YHR213W-A conformational changes

  • Yeast two-hybrid derivative systems using nanobody fusions

  • Real-time monitoring of protein expression and localization changes

• Structural biology applications:

  • Nanobodies as crystallization chaperones for YHR213W-A structural studies

  • Cryo-EM analysis using nanobody-decorated proteins

  • NMR studies with stabilizing nanobodies to determine solution structures

  • Hydrogen-deuterium exchange mass spectrometry with protective nanobodies